Insulin glargine/lixisenatide

Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

Retrieved on: 
Thursday, March 16, 2023

Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

Key Points: 
  • Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance
    Paris, March 16, 2023.
  • Sanofi announces that it will cut the list price of Lantus (insulin glargine injection) 100 Units/mL, its most widely prescribed insulin in the U.S., by 78 percent.
  • The company also will establish a $35 cap on out-of-pocket costs for Lantus for all patients with commercial insurance, underscoring its longstanding commitment to offer affordable access to medicines.
  • Finally, Sanofi will also cut the list price of its short-acting Apidra (insulin glulisine injection) 100 Units/mL by 70%.

Insulin Drugs Global Market Report 2023

Retrieved on: 
Monday, February 20, 2023

The global insulin drugs market will grow from $32.83 billion in 2022 to $36.50 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%.

Key Points: 
  • The global insulin drugs market will grow from $32.83 billion in 2022 to $36.50 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%.
  • The regions covered in the insulin drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The insulin drugs market research report is one of a series of new reports that provides insulin drugs market statistics, including insulin drugs industry global market size, regional shares, competitors with an insulin drugs market share, detailed insulin drugs market segments, market trends and opportunities, and any further data you may need to thrive in the insulin drugs industry.
  • This insulin drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The Senior Citizens League Says, "You Better Check Your Medicare Drug Plan"

Retrieved on: 
Monday, October 31, 2022

WASHINGTON, Oct. 26, 2022 /PRNewswire-PRWeb/ -- The recently enacted Inflation Reduction Act requires Medicare Part D plans to cap insulin costs at $35 per month per covered prescription starting in 2023, but to get the savings, diabetic Medicare beneficiaries first need to confirm that their insulin will be covered by their plan next year, warns the Senior Citizens League (TSCL). "If your insulin isn't covered by your plan, the $35 cap will not apply and you could wind up with thousands of dollars in pharmacy bills," says Mary Johnson, a Medicare, and Social Security policy analyst for The Senior Citizen League.

Key Points: 
  • For the past 17 years, Johnson has been helping friends and family check and compare their Medicare coverage options during the annual Medicare Open Enrollment Period.
  • Johnson, who has experience doing drug plan searches, immediately hit a dead end on her first search attempt using the Medicare Drug Plan Finder .
  • "The drug input in the Medicare Drug Plan Finder automatically defaults to the generic name of the drug unless the user overrides it and clicks on 'brand.'
  • With 1.2 million supporters, The Senior Citizens League is one of the nation's largest nonpartisan seniors' groups.

Press Release: Strong execution in Q2 drives full-year 2022 guidance upgrade and delivers rich R&D news flow in Immunology and Rare Disease

Retrieved on: 
Thursday, July 28, 2022

Applying average July 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated between +7.5% to +8.5%

Key Points: 
  • Applying average July 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated between +7.5% to +8.5%
    Our performance in the second quarter was again marked by higher sales across our key growth drivers and outstanding financial results leading us to upgrade our business EPS guidance for the full-year.
  • Notably, we saw significant growth momentum from our Specialty Care business, mainly driven by Dupixent.
  • While we continue to increase our investment in R&D, we delivered important pipeline milestones such as the approval of Dupixent in its fourth disease indication, Eosinophilic Esophagitis.
  • Earlier this month, we had the opportunity to showcase at ISTH the transformative potential of efanesoctocog alfa, the first factor replacement therapy for hemophilia A to receive FDA Breakthrough Therapy Designation.

Denali Therapeutics Announces Initiation of Phase 2 Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in Cutaneous Lupus Erythematosus (CLE) Patients

Retrieved on: 
Monday, June 28, 2021

Denali and Sanofi entered into a broad collaboration inOctober 2018for the global development and commercialization of RIPK1 inhibitors.

Key Points: 
  • Denali and Sanofi entered into a broad collaboration inOctober 2018for the global development and commercialization of RIPK1 inhibitors.
  • Under the agreement, Denali will receive a milestone payment of $15 million related to the Phase 2 study with DNL758 from Sanofi.
  • Sanofi is responsible for the development and commercialization of DNL758 and covers all costs related to DNL758.
  • Further information on the Phase 2 clinical study of DNL758for CLE (study number NCT04781816) can be accessed on theClinicalTrials.govwebsite or by clicking here .

China Insulin Glargine Market, 2018-2022 - Sales Value of Insulin Glargine has Been Growing Since it Entered China and Exceeded CNY 800 Million in 2017

Retrieved on: 
Wednesday, August 15, 2018

According to WHO's data, there are about 110 million diabetics in China, about 1/10 of China's adults.

Key Points: 
  • According to WHO's data, there are about 110 million diabetics in China, about 1/10 of China's adults.
  • Insulin Glargine is the first long-acting insulin produced by simulating recombinant DNA technology.
  • The sales value has been growing since Insulin Glargine entered China and exceeded CNY 800 million in 2017.
  • 2 Sales of Insulin Glargine in China, 2013-2017
    2.3 Sales of Insulin Glargine by Dosage Form in China, 2013-2017
    3 Analysis onMajor Insulin Glargine Manufacturers in China, 2013-2017
    3.4 Zhuhai United Laboratories Co., Ltd.
    3.4.2 Sales of Zhuhai United Laboratories Co., Ltd.'s Insulin Glargine in China
    4 Prices of Different Manufacturers' Insulin Glargine in China, 2017-2018
    4.4 Zhuhai United Laboratories Co., Ltd. (USLEN)
    5 Prospect of Chinese Insulin Glargine Market, 2018-2022